Replication fork stability confers chemoresistance in BRCA-deficient cells

Area of Science:

• Molecular Biology
• Cancer Research
• Genetics

Background:

• Cells deficient in Brca1 and Brca2 genes exhibit impaired homologous recombination repair of DNA double-strand breaks.
• This deficiency leads to hypersensitivity to DNA-damaging agents such as cisplatin and poly(ADP-ribose) polymerase (PARP) inhibitors.

Purpose of the Study:

• To investigate the protective role of PTIP (a protein within the MLL3/4 complex) in Brca1/2-deficient cells.
• To elucidate the underlying mechanisms by which PTIP deficiency confers resistance to DNA-damaging agents.

Main Methods:

• Analysis of Brca1/2-deficient cells with and without PTIP.
• Assessment of homologous recombination activity at DNA double-strand breaks.
• Investigation of MRE11 nuclease recruitment to stalled replication forks.
• Evaluation of nascent DNA strand degradation.
• Study of drug resistance in Brca2-deficient tumor cells.

Main Results:

• Loss of PTIP protects Brca1/2-deficient cells from DNA damage and rescues lethality in Brca2-deficient embryonic stem cells.
• PTIP deficiency does not restore homologous recombination but inhibits MRE11 recruitment to stalled replication forks.
• Inhibition of MRE11 recruitment protects nascent DNA strands from degradation, conferring resistance.
• Replication fork protection is associated with resistance to PARP inhibitors and cisplatin in Brca2-deficient tumor cells.

Conclusions:

• PTIP plays a crucial role in protecting Brca1/2-deficient cells from DNA damage through replication fork protection, not homologous recombination repair.
• Acquisition of resistance to chemotherapeutic agents in Brca2-deficient tumors can occur via replication fork protection mechanisms.
• Disruption of various proteins, including PARP1 and CHD4, converges on replication fork protection, highlighting complex drug resistance pathways.